ALLO

Allogene Therapeutics, Inc.

Price Chart

Latest Quote

$1.85

-0.08 (-4.15%)

Current Price

Previous Close	$1.93
Open	$1.94
Day High	$1.94
Day Low	$1.84
Volume	5,354,770

Fetched: 2026-07-14T23:03:40

Stock Information

Shares Outstanding	345.15M
Total Debt	$81.05M
Cash Equivalents	$266.89M
Net Income	$-173.76M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$638.54M
EPS (TTM)	$-0.77
Exchange	NMS

🌐 Visit Website

Recent Price History

Date	Close	Volume
2026-07-17	$1.79	4,939,700
2026-07-16	$1.79	6,300,100
2026-07-15	$1.90	6,039,700
2026-07-14	$1.85	5,422,400
2026-07-13	$1.93	8,941,900
2026-07-10	$2.00	7,779,900
2026-07-09	$2.10	6,544,200
2026-07-08	$2.12	12,427,600
2026-07-07	$2.15	14,393,100
2026-07-06	$2.09	10,911,900
2026-07-02	$2.08	9,135,000
2026-07-01	$2.11	12,920,000
2026-06-30	$2.08	17,982,800
2026-06-29	$2.22	14,664,000
2026-06-26	$2.13	25,919,200
2026-06-25	$2.06	9,354,000
2026-06-24	$2.05	9,550,700
2026-06-23	$2.07	4,811,700
2026-06-22	$2.10	6,573,200
2026-06-18	$2.00	23,548,200

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

📰 Latest News

Kyverna Therapeutics Sinks 13%: Here’s Why

24/7 Wall St. • 2026-07-10T19:59:59Z

Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial

Exec Edge • 2026-06-30T20:10:59Z

Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions

Simply Wall St. • 2026-06-28T05:05:19Z

How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease

Insider Monkey • 2026-06-17T15:17:00Z

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?

Zacks • 2026-06-12T15:30:02Z

FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases

Exec Edge • 2026-06-09T21:19:19Z

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio

Insider Monkey • 2026-06-07T17:57:43Z

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1

Zacks • 2026-05-14T14:17:00Z

Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders

24/7 Wall St. • 2026-05-14T13:20:55Z

Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ...

GuruFocus.com • 2026-05-14T05:00:51Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$22,000	$95,000	$156,000
Operating Revenue	$0	$22,000	$95,000	$156,000
Expenses
Interest Expense	$1,075,000	$181,000	$0	-
Total Expenses	$206,933,000	$257,504,000	$314,587,000	$335,692,000
Other Income Expense	$-2,167,000	$-19,637,000	$-31,080,000	$-9,444,000
Other Non Operating Income Expenses	$215,000	$-3,920,000	$-17,835,000	$-9,444,000
Net Non Operating Interest Income Expense	$18,214,000	$19,972,000	$18,307,000	$4,566,000
Interest Expense Non Operating	$1,075,000	$181,000	$0	-
Operating Expense	$206,933,000	$257,504,000	$314,587,000	$335,692,000
General And Administrative Expense	$56,781,000	$65,205,000	$71,673,000	$79,305,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-190,886,000	$-257,590,000	$-327,265,000	$-340,414,000
Net Interest Income	$18,214,000	$19,972,000	$18,307,000	$4,566,000
Interest Income	$19,289,000	$20,153,000	$18,307,000	$4,566,000
Normalized Income	$-188,504,000	$-245,173,570	$-314,020,000	$-340,414,000
Net Income From Continuing And Discontinued Operation	$-190,886,000	$-257,590,000	$-327,265,000	$-340,414,000
Total Operating Income As Reported	$-209,315,000	$-273,199,000	$-327,737,000	$-335,536,000
Net Income Common Stockholders	$-190,886,000	$-257,590,000	$-327,265,000	$-340,414,000
Net Income	$-190,886,000	$-257,590,000	$-327,265,000	$-340,414,000
Net Income Including Noncontrolling Interests	$-190,886,000	$-257,590,000	$-327,265,000	$-340,414,000
Net Income Continuous Operations	$-190,886,000	$-257,590,000	$-327,265,000	$-340,414,000
Pretax Income	$-190,886,000	$-257,147,000	$-327,265,000	$-340,414,000
Special Income Charges	$-2,382,000	$-15,717,000	$-13,245,000	-
Interest Income Non Operating	$19,289,000	$20,153,000	$18,307,000	$4,566,000
Operating Income	$-206,933,000	$-257,482,000	$-314,492,000	$-335,536,000
Per Share
Diluted EPS	$-0.87	$-1.32	$-2.09	$-2.32
Basic EPS	$-0.87	$-1.32	$-2.09	$-2.32
Other
Tax Effect Of Unusual Items	$0	$-3,300,570	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-175,070,000	$-227,610,000	$-299,821,000	$-321,241,000
Total Unusual Items	$-2,382,000	$-15,717,000	$-13,245,000	-
Total Unusual Items Excluding Goodwill	$-2,382,000	$-15,717,000	$-13,245,000	-
Reconciled Depreciation	$12,359,000	$13,639,000	$14,199,000	$14,295,000
EBITDA (Bullshit earnings)	$-177,452,000	$-243,327,000	$-313,066,000	$-321,241,000
EBIT	$-189,811,000	$-256,966,000	$-327,265,000	$-335,536,000
Diluted Average Shares	$220,622,669	$194,811,756	$156,931,778	$143,147,165
Basic Average Shares	$220,622,669	$194,811,756	$156,931,778	$143,147,165
Diluted NI Availto Com Stockholders	$-190,886,000	$-257,590,000	$-327,265,000	$-340,414,000
Tax Provision	$0	$443,000	$0	-
Impairment Of Capital Assets	$2,382,000	$15,717,000	$13,245,000	-
Research And Development	$150,152,000	$192,299,000	$242,914,000	$256,387,000
Selling General And Administration	$56,781,000	$65,205,000	$71,673,000	$79,305,000
Other Gand A	$56,781,000	$65,205,000	$71,673,000	$79,305,000

Fetched: 2026-07-04

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$292,542,000	$422,179,000	$512,233,000	$666,882,000
Total Assets	$415,905,000	$548,710,000	$642,837,000	$821,579,000
Total Non Current Assets	$158,156,000	$245,324,000	$183,722,000	$292,755,000
Other Non Current Assets	$37,386,000	$33,390,000	$16,896,000	$19,856,000
Investmentin Financial Assets	$8,043,000	$80,673,000	$0	$59,151,000
Current Assets	$257,749,000	$303,386,000	$459,115,000	$528,824,000
Other Current Assets	$7,539,000	$10,910,000	$10,418,000	$11,504,000
Cash Cash Equivalents And Short Term Investments	$250,210,000	$292,476,000	$448,697,000	$517,320,000
Cash And Cash Equivalents	$51,688,000	$75,218,000	$83,155,000	$61,904,000
Cash Equivalents	-	-	$78,536,000	-
Cash Financial	-	-	$4,619,000	-
Prepaid Assets	-	-	-	-
Debt
Total Debt	$83,253,000	$90,756,000	$95,121,000	$101,124,000
Long Term Debt And Capital Lease Obligation	$75,045,000	$83,247,000	$88,346,000	$95,122,000
Current Debt And Capital Lease Obligation	$8,208,000	$7,509,000	$6,775,000	$6,002,000
Liabilities
Total Liabilities Net Minority Interest	$123,363,000	$126,531,000	$130,604,000	$154,697,000
Total Non Current Liabilities Net Minority Interest	$90,849,000	$91,008,000	$93,525,000	$100,969,000
Other Non Current Liabilities	$15,804,000	$7,761,000	$5,179,000	$5,847,000
Current Liabilities	$32,514,000	$35,523,000	$37,079,000	$53,728,000
Payables And Accrued Expenses	$14,065,000	$15,868,000	$17,553,000	$29,696,000
Payables	$4,270,000	$5,394,000	$5,897,000	$13,890,000
Accounts Payable	$4,270,000	$5,394,000	$5,897,000	$13,890,000
Other Current Liabilities	-	-	$86,000	-
Current Deferred Liabilities	-	-	$86,000	$95,000
Equity
Common Stock Equity	$292,542,000	$422,179,000	$512,233,000	$666,882,000
Total Equity Gross Minority Interest	$292,542,000	$422,179,000	$512,233,000	$666,882,000
Stockholders Equity	$292,542,000	$422,179,000	$512,233,000	$666,882,000
Gains Losses Not Affecting Retained Earnings	$269,000	$-89,000	$-955,000	$-9,926,000
Other Equity Adjustments	$269,000	$-89,000	$-955,000	$-9,926,000
Retained Earnings	$-2,010,709,000	$-1,819,823,000	$-1,562,233,000	$-1,234,968,000
Long Term Equity Investment	-	$0	$3,645,000	$17,317,000
Other
Ordinary Shares Number	$229,413,523	$212,210,597	$168,642,238	$144,438,304
Share Issued	$229,413,523	$212,210,597	$168,642,238	$144,438,304
Tangible Book Value	$292,542,000	$422,179,000	$512,233,000	$666,882,000
Invested Capital	$292,542,000	$422,179,000	$512,233,000	$666,882,000
Working Capital	$225,235,000	$267,863,000	$422,036,000	$475,096,000
Capital Lease Obligations	$83,253,000	$90,756,000	$95,121,000	$101,124,000
Total Capitalization	$292,542,000	$422,179,000	$512,233,000	$666,882,000
Additional Paid In Capital	$2,302,753,000	$2,241,879,000	$2,075,252,000	$1,911,632,000
Capital Stock	$229,000	$212,000	$169,000	$144,000
Common Stock	$229,000	$212,000	$169,000	$144,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$75,045,000	$83,247,000	$88,346,000	$95,122,000
Current Capital Lease Obligation	$8,208,000	$7,509,000	$6,775,000	$6,002,000
Pensionand Other Post Retirement Benefit Plans Current	$10,241,000	$12,146,000	$12,665,000	$17,935,000
Current Accrued Expenses	$9,795,000	$10,474,000	$11,656,000	$15,806,000
Investments And Advances	$8,043,000	$80,673,000	$3,645,000	$76,468,000
Available For Sale Securities	$8,043,000	$80,673,000	-	$59,151,000
Net PPE	$112,727,000	$131,261,000	$163,181,000	$196,431,000
Accumulated Depreciation	$-72,533,000	$-62,538,000	$-51,084,000	$-36,885,000
Gross PPE	$185,260,000	$193,799,000	$214,265,000	$233,316,000
Leases	$107,537,000	$108,127,000	$108,621,000	$108,550,000
Other Properties	$68,636,000	$76,800,000	$96,860,000	$116,193,000
Machinery Furniture Equipment	$9,087,000	$8,872,000	$8,784,000	$8,545,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$198,522,000	$217,258,000	$365,542,000	$455,416,000
Current Deferred Revenue	-	-	$86,000	$95,000
Construction In Progress	-	-	$0	$28,000

Fetched: 2026-07-04

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-149,632,000	$-200,994,000	$-239,249,000	$-225,710,000
Operating Activities
Operating Cash Flow	$-149,246,000	$-200,300,000	$-237,733,000	$-220,519,000
Cash Flow From Continuing Operating Activities	$-149,246,000	$-200,300,000	$-237,733,000	$-220,519,000
Operating Gains Losses	-	$1,688,000	$10,672,000	$12,883,000
Investing Activities
Capital Expenditure	$-386,000	$-694,000	$-1,516,000	$-5,191,000
Investing Cash Flow	$95,559,000	$75,688,000	$163,289,000	$106,159,000
Cash Flow From Continuing Investing Activities	$95,559,000	$75,688,000	$163,289,000	$106,159,000
Financing Activities
Issuance Of Capital Stock	$22,354,000	$112,047,000	$91,112,000	$0
Financing Cash Flow	$30,157,000	$116,675,000	$95,695,000	$2,950,000
Cash Flow From Continuing Financing Activities	$30,157,000	$116,675,000	$95,695,000	$2,950,000
Net Other Financing Charges	$6,908,000	$2,280,000	-	-
Net Common Stock Issuance	$22,354,000	$112,047,000	$91,112,000	$0
Common Stock Issuance	$22,354,000	$112,047,000	$91,112,000	$0
Other
End Cash Position	$61,980,000	$85,510,000	$93,447,000	$72,196,000
Beginning Cash Position	$85,510,000	$93,447,000	$72,196,000	$183,606,000
Changes In Cash	$-23,530,000	$-7,937,000	$21,251,000	$-111,410,000
Proceeds From Stock Option Exercised	$895,000	$2,348,000	$4,583,000	$2,950,000
Net Investment Purchase And Sale	$95,945,000	$76,382,000	$164,805,000	$111,350,000
Sale Of Investment	$234,202,000	$437,857,000	$603,434,000	$359,459,000
Purchase Of Investment	$-138,257,000	$-361,475,000	$-438,629,000	$-248,109,000
Net PPE Purchase And Sale	$-386,000	$-694,000	$-1,516,000	$-5,191,000
Purchase Of PPE	$-386,000	$-694,000	$-1,516,000	$-5,191,000
Change In Working Capital	$-10,877,000	$-24,799,000	$-21,307,000	$3,897,000
Change In Other Working Capital	$-2,706,000	$-20,773,000	$-3,000	$-21,000
Change In Other Current Liabilities	$-6,368,000	$-6,048,000	$-6,613,000	$-1,882,000
Change In Other Current Assets	$-1,290,000	$4,279,000	$-1,455,000	$-3,334,000
Change In Payables And Accrued Expense	$-3,751,000	$-1,765,000	$-14,325,000	$6,617,000
Change In Accrued Expense	$-2,520,000	$-1,262,000	$-6,823,000	$1,749,000
Change In Payable	$-1,231,000	$-503,000	$-7,502,000	$4,868,000
Change In Account Payable	$-1,231,000	$-503,000	$-7,502,000	$4,868,000
Change In Prepaid Assets	$3,238,000	$-492,000	$1,086,000	$2,517,000
Other Non Cash Items	$4,355,000	$5,250,000	$6,581,000	$2,329,000
Stock Based Compensation	$37,642,000	$51,743,000	$65,951,000	$83,600,000
Asset Impairment Charge	$2,382,000	$17,674,000	$20,245,000	-
Amortization Of Securities	$-4,221,000	$-8,348,000	$-6,809,000	$2,891,000
Deferred Tax	$0	$443,000	$0	-
Deferred Income Tax	$0	$443,000	$0	-
Depreciation Amortization Depletion	$12,359,000	$13,639,000	$14,199,000	$14,295,000
Depreciation And Amortization	$12,359,000	$13,639,000	$14,199,000	$14,295,000
Earnings Losses From Equity Investments	$0	$1,688,000	$10,672,000	$12,883,000
Net Income From Continuing Operations	$-190,886,000	$-257,590,000	$-327,265,000	$-340,414,000
Net Business Purchase And Sale	-	-	$0	$0
Purchase Of Business	-	-	$0	$0
Amortization Cash Flow	-	-	-	$0
Amortization Of Intangibles	-	-	-	$0
Depreciation	-	-	-	$14,295,000

Fetched: 2026-07-04